# Bruker account plan

> Bruker makes scientific instruments and diagnostics (NMR, mass spectrometry, X-ray, microscopy): $3,436.5 million FY2025 revenue, about 11,085 staff.

## At a glance

Bruker, headquartered in Billerica, Massachusetts, develops, manufactures and distributes scientific instruments and analytical and diagnostic solutions across magnetic resonance, mass spectrometry, chromatography, X-ray, microscopy, metrology and molecular spectroscopy. Its customers are academic and government research facilities, pharma and biotech companies, hospitals and clinical microbiology labs, semiconductor and industrial companies, and defense and security agencies, served by direct sales forces in North America, Europe, China, Japan and Asia Pacific plus distributors. FY2025 revenue was $3,436.5 million (+2.1%, organic -3.7%), with GAAP operating income of $68.2 million and a non-GAAP operating margin of 12.6%. It had approximately 11,085 employees at December 31, 2025, about 20.2% in the United States. Frank H. Laukien is Chairman, President and CEO, and Laukien family members owned about 32% of common stock at the end of 2025.

## Business units

- **BSI BIOS (Biosystems)** ($1,154.8 million in 9M 2026, about 45.5% (computed)): Formed on July 1, 2026 from BioSpin (NMR, EPR, preclinical imaging), SciY software, Chemspeed lab automation, Daltonics mass spectrometry, Optics and the newly acquired Mimetas. Q3 2026 revenue was $397.2 million (+1.5%), with strength in IR/Raman and mass spectrometry and softer NMR. It is led by Group President Juergen Srega.
- **BSI BMID (Microbiology and Infection Diagnostics)** ($395.8 million in 9M 2026, about 15.6% (computed)): Microbial identification (MALDI Biotyper), molecular diagnostics including the ELITech Genius platforms, antimicrobial susceptibility and resistance testing and microbial genomics, sold to clinical labs, public health agencies and industrial, pharma and food safety markets. Q3 2026 revenue was $133.6 million (+2.6%) with a 24.6% operating margin. Led by Dr. Wolfgang Busch.
- **BSI NANO** ($770.4 million in 9M 2026, about 30.4% (computed)): X-ray, atomic force microscopy, fluorescence microscopy, electron microscope analytics, semiconductor metrology and defect detection, and spatial biology and cellular analysis. Q3 2026 revenue was $263.1 million (-1.3%), and the unit took a $174.5 million goodwill impairment on spatial biology; semiconductor metrology bookings grew more than 30% year to date.
- **BEST (Bruker Energy & Supercon Technologies)** ($223.1 million in 9M 2026, about 8.8% (computed)): Low and high temperature superconductors for MRI, NMR, fusion and high-energy physics, plus EUV/XUV technologies for semiconductor companies and research labs. Q3 2026 revenue rose 11.2% to $82.1 million on hospital and clinical demand, with research orders driven by ITER, fusion and light sources.

## Strategic priorities

- **Cost-out programme**: A cost savings initiative announced in August 2025 targeted $100 million to $120 million of annualized savings by the end of 2026; the CFO said in Q3 2026 Bruker is on track for a $140 million annualized run rate. The new group structure is expected to add $20 million of cost reductions in fiscal year 2027.
- **Margin recovery**: Management aims to drive back towards a 20% EBIT operating margin, then the low 20s, and expects more than 100 basis points of further operating margin expansion in 2027 with double-digit EPS growth.
- **Simpler segment structure**: Effective July 1, 2026 Bruker reorganised into four groups (Biosystems, Nano, BMID and BEST) to streamline decision making, accountability and customer focus.
- **Semiconductor metrology and deep tech**: Semiconductor metrology bookings grew more than 30% year to date in 2026 on demand for high bandwidth memory and advanced packaging; the deep tech portfolio is about 15% of the business and semi metrology has about a 30% EBIT margin.
- **Post-genomic research and diagnostics**: New timsTOF and timsOmni proteomics workflows, the Mimetas organ-on-a-chip platform and molecular diagnostics growth, which the CEO calls a high single-digit growth area long term.

## Latest results

In Q3 2026 revenue was $874.0 million, up 1.6% from $860.5 million, with organic growth of 0.7%. Non-GAAP operating margin rose to 16.3% from 12.3% and non-GAAP EPS rose 24.4% to $0.56, while the GAAP operating loss of $91.0 million reflected $174.5 million of goodwill impairment. Nine-month revenue was $2,535.9 million (+3.1%, organic -0.3%). BSI book-to-bill exceeded one for the fifth consecutive quarter, and U.S. academic bookings grew for the first time since the 2025 NIH funding disruption. FY2026 guidance is revenue of $3.52 to $3.56 billion and non-GAAP EPS of $2.10 to $2.15.

## Investments and deals

- **Tofwerk and Mimetas**: Bruker acquired the remaining 60.0% of Tofwerk on January 6, 2026 ($74.0 million net of cash) and a majority of Mimetas B.V. on August 7, 2026 ($60.7 million).
- **Atinary Technologies**: A strategic collaboration and minority investment integrating Chemspeed lab automation and Bruker instruments into agentic AI chemistry workflows.
- **Earlier platform acquisitions**: 2024 acquisitions totalled $1,599.6 million, including ELITechGroup and NanoString; 2025 acquisitions fell to $103.3 million as the focus moved to integration.
- **Balance sheet repair**: In September 2025 Bruker issued $690 million of 6.375% Mandatory Convertible Preferred Stock to repay term loans and revolver borrowings; total debt was $1.7 billion at September 30, 2026 and net leverage 2.4x.

## Challenges and risks

- **Tariffs**: U.S. tariffs on imports from Germany and Switzerland reduced bookings, revenue and margins in 2025; refunds were filed after the February 20, 2026 Supreme Court ruling, but other tariff programmes remain.
- **U.S. academic funding**: Reduced and delayed NIH, NSF and DOE funding had a material adverse effect; U.S. academic revenue was down more than $15 million year on year in Q2 2026.
- **Goodwill impairments**: Spatial biology and cellular analysis took $211.0 million of goodwill impairment in 2026 and Chemspeed $98.4 million, after operating results below expectations.
- **Weak industrial, biopharma and Asia demand**: Slower industrial and semiconductor demand drove the FY2025 organic decline, and nine-month 2026 Asia Pacific revenue fell to $673.7 million from $727.2 million.

## What leadership says

> "we expect revenue growth acceleration, continued margin expansion and double-digit EPS growth in FY27." — Frank H. Laukien, Chairman, President and CEO, Bruker Q3 2026 results press release, November 4, 2026

> "We are on track to achieve our $140 million annualized run rate cost-out target." — Gerald N. Herman, EVP and CFO, Bruker Q3 2026 earnings call, November 4, 2026

> "our goal is to drive back towards a 20% EBIT operating margin as quickly as possible and then more gradually move up to the low 20s in EBIT and mid-20s in EBITDA" — Frank H. Laukien, Chairman, President and CEO, Bruker Q2 2026 earnings call, August 2026


## Where a supplier can help

- **Cost-out and procurement savings**: The annualized cost-out target touches supply chain, manufacturing, commercial operations, administration and R&D, so suppliers that lower cost in those functions fit the programme.
- **Integration of acquired businesses**: Tofwerk, Mimetas and the earlier ELITechGroup and NanoString deals, plus the July 2026 regrouping, create integration work in systems, data and processes.
- **Semiconductor metrology capacity**: Semi metrology orders with 9 to 24 month lead times convert mostly in fiscal 2027 and 2028, which calls for manufacturing, components and logistics support for that business.
- **Tariff and supply chain resilience**: Tariffs on German and Swiss imports and limited-source components are stated risks; trade compliance and alternative sourcing services address them.

_Tamtam's reading of the priorities and challenges above, not the company's own words._

## Key documents

### [Form 10-K for the fiscal year ended December 31, 2025](https://www.sec.gov/Archives/edgar/data/1109354/000119312526082523/brkr-20251231.htm)

Annual report · 2026-02-27

- Bruker is a Billerica (Massachusetts) developer, manufacturer and distributor of high-performance scientific instruments and analytical and diagnostic solutions (magnetic resonance, mass spectrometry, chromatography, X-ray, microscopy, metrology, molecular spectroscopy); approximately 11,085 employees at December 31, 2025, about 20.2% of them in the United States.
- FY2025 revenue was $3,436.5 million, up 2.1% (CER revenue down 0.2%, organic revenue down 3.7%); GAAP gross margin fell to 45.9% from 49.0% and GAAP operating income to $68.2 million (2.0% margin) from $253.1 million; non-GAAP operating margin was 12.6% vs 15.4%.
- Four reportable segments in FY2025: BSI CALID $1,210.2 million (+10.7%), BSI NANO $1,084.3 million (-1.3%), BSI BioSpin $878.8 million (-3.0%) and BEST $270.9 million (-4.3%).
- Headwinds named by the filing: U.S. tariffs on imports from Germany and Switzerland, disruption of U.S. academic funding (NIH, NSF, DOE), delayed Chinese stimulus spending (China revenue flat at $475.8 million), slower industrial and semiconductor demand and a declining U.S. Dollar.
- A cost savings initiative announced in August 2025 targets approximately $100 million to $120 million of annualized cost reductions by the end of 2026, across supply chain, manufacturing, commercial, administrative and R&D.
- Goodwill impairment of $96.5 million on Bruker Spatial Biology (BSI NANO) and Automation (BSI BioSpin); net loss attributable to Bruker of $8.6 million vs net income of $113.1 million in 2024.
- Balance sheet: $690 million 6.375% Mandatory Convertible Preferred Stock issued in September 2025 used to repay debt; total debt $1.9 billion and $298.8 million cash at year end; free cash flow $43.3 million.
- Backlog (remaining performance obligations) rose to $2,569.4 million from $2,090.4 million, mainly on higher BEST bookings; 2025 acquisitions included Recipe (clinical LC-MS assay kits) and AST Revolution (rapid antimicrobial susceptibility testing).
- Revenue mix by geography: Europe excluding Germany 27.7%, United States 25.9%, Asia Pacific excluding China 16.1%, China 13.8%, Germany 8.6%; the Laukien family, including Chairman, President and CEO Frank Laukien, owned about 32% of common stock.

### [Form 10-Q for the quarter ended September 30, 2026](https://www.sec.gov/Archives/edgar/data/1109354/000119312526449731/brkr-20260930.htm)

Interim report · 2026-11-05

- Q3 2026 revenue was $874.0 million, up 1.6% year on year (organic +0.7%, CER +2.4%); nine-month revenue $2,535.9 million, up 3.1% (organic -0.3%).
- Effective July 1, 2026 Bruker reorganised into four reportable segments: BSI BIOS (BioSpin, SciY, Chemspeed Technologies, Daltonics, Optics, Mimetas), BSI BMID (Microbiology, Molecular Diagnostics, Biomedical Systems), BSI NANO and BEST.
- Q3 segment revenue: BSI BIOS $397.2 million (+1.5%), BSI NANO $263.1 million (-1.3%), BSI BMID $133.6 million (+2.6%), BEST $82.1 million (+11.2%).
- Gross margin rose to 49.1% from 44.1% on cost savings, lower restructuring and mix; non-GAAP operating margin 16.3% vs 12.3%; SG&A fell to 25.9% of revenue.
- GAAP operating loss of $91.0 million because of a $174.5 million goodwill impairment that wrote off the remaining goodwill of the merged Bruker Spatial Biology and Cellular Analysis (BSB&CA) unit after changes in the competitive landscape; nine-month goodwill impairments total $309.4 million, including $98.4 million on Chemspeed Technologies (formerly Automation).
- 2026 acquisitions: the remaining 60.0% of Tofwerk (January 6, 2026) and a majority of Mimetas B.V. (August 7, 2026), both in BSI BIOS; a $34.6 million impairment was taken on the NovAliX investment.
- Restructuring: the Corporate-wide plan finished in Q2 2026 ($74.3 million cumulative charges); a BSI NANO plan merges divisions by end 2026; a BSI Biosystems plan expects another $4.0 million to $6.0 million of charges, finishing in H1 2027.
- Most IEEPA tariff refund requests had been approved by September 30, 2026; nine-month operating cash flow was $112.0 million vs -$95.7 million; total debt $1.7 billion and cash $119.7 million.

### [Bruker Reports Third Quarter 2026 Financial Results (press release)](https://www.sec.gov/Archives/edgar/data/1109354/000119312526446176/brkr-ex99_1.htm)

Interim report · 2026-11-04

- Q3 2026 revenue $874.0 million, up 1.6% year on year; organic growth 0.7%, acquisitions 1.7%, currency -0.8%.
- BSI revenue $793.9 million (+0.8%, organic -0.4%); BEST revenue $82.1 million (+11.2%, organic +11.8%).
- Non-GAAP operating margin 16.3%, up 400 bps; non-GAAP diluted EPS $0.56, up 24.4%; GAAP diluted loss per share $(0.81) after $174.5 million of goodwill impairment.
- FY2026 outlook: revenue $3.52 to $3.56 billion (2.5% to 3.5% reported growth), organic growth 1% to 2%, M&A about 1.5%, currency neutral; non-GAAP EPS $2.10 to $2.15, up 15% to 17%.
- Frank Laukien: fifth consecutive quarter of BSI book-to-bill above one, BSI organic bookings and backlog both up mid-single digits year to date, and an expectation of revenue growth acceleration, margin expansion and double-digit EPS growth in FY27.
- Q3 free cash flow $96.7 million vs -$54.1 million a year earlier; cash $119.7 million and long-term debt $1,703.0 million at September 30, 2026.
- Revenue by end-customer geography in Q3: Europe $320.2 million, Asia Pacific $247.7 million, United States $231.2 million, Other $74.9 million.

### [Bruker Q3 2026 earnings call transcript](https://www.fool.com/earnings/call-transcripts/2026/11/04/bruker-brkr-q3-2026-earnings-call-transcript/)

Executive talk · Frank H. Laukien, Chairman, President and Chief Executive Officer · 2026-11-04

- Frank Laukien: fifth consecutive quarter of BSI book-to-bill above one; U.S. academic and government BSI organic bookings grew double digits in Q3, the first year-on-year growth since the 2025 NIH funding disruption.
- China BSI organic bookings were up over 20% in Q3 and year to date; semiconductor metrology bookings grew more than 30% year to date, driven by AI demand for logic foundries, high bandwidth memory and advanced packaging, converting mostly in FY2027.
- Q3 revenue $874 million (+1.6%, organic 0.7%); non-GAAP operating margin 16.3%; non-GAAP EPS $0.56, up 24%; free cash flow improved $151 million; net leverage 2.4x, below target.
- Mimetas, a humanized organ-on-a-chip (NAM) platform, was acquired as a majority stake to complement multi-omics, spatial and structural biology for drug discovery; an investment in Atinary Technologies links Chemspeed automation and Bruker instruments to agentic AI labs.
- CFO Gerald Herman: on track for the $140 million annualized cost-out target; FY2026 guidance of $3.52 to $3.56 billion revenue and $2.10 to $2.15 non-GAAP EPS; Laukien expects Q4 to be about a $1 billion revenue quarter.
- 2027 framing: double-digit EPS growth, more than 100 basis points of further operating margin expansion and lower mid-single-digit organic growth; 2027 called "a transition year".
- BMID seen as a high single-digit growth area long term; FDA clearance hoped for the Wave antibiotic susceptibility test; BEST orders strong on ITER, fusion and high-energy physics projects.

### [Bruker Q2 2026 earnings call transcript](https://www.fool.com/earnings/call-transcripts/2026/08/11/bruker-brkr-q2-2026-earnings-call-transcript/)

Executive talk · Frank H. Laukien, Chairman, President and Chief Executive Officer · 2026-08-11

- Q2 2026 marked a return to organic revenue growth: revenue $839 million, up 5.2%, organic 2.8% (3.4% excluding tariff refunds); non-GAAP operating margin 14.1%; non-GAAP EPS $0.49, up 53%.
- BSI organic bookings grew 10%, a fourth consecutive quarter of book-to-bill above 1.0; biopharma bookings grew more than 20%; U.S. academic orders remained weak while Europe and China academic orders were up strongly.
- Deep tech: semiconductor tools and energy research orders both grew over 50% in Q2; semi metrology has about a 30% EBIT margin and 9 to 24 month lead times; deep tech is about 15% of the portfolio.
- New structure from July 1, 2026: Bruker Biosystems Group (BioSpin, Daltonics, Optics) led by Juergen Srega; BMID established as a group under Dr. Wolfgang Busch; expected to drive an additional $20 million of cost reductions in fiscal 2027.
- Cost savings on track for $140 million annualized in 2026; about $30 million delivered in Q2.
- FY2026 guidance updated for currency and tax: revenue $3.54 to $3.57 billion, organic growth 1% to 2%, non-GAAP EPS $2.10 to $2.15; about $20 million of semi revenue shifted from Q3 to Q4.
- Long-term goal: back towards a 20% operating margin as quickly as possible, then low 20s EBIT and mid-20s EBITDA.

## Questions about Bruker

### What does Bruker do?

Bruker develops, manufactures and distributes scientific instruments and analytical and diagnostic solutions, including NMR, mass spectrometry, X-ray, microscopy and semiconductor metrology, for research, pharma, clinical and industrial customers.

### What is Bruker's revenue?

FY2025 revenue was $3,436.5 million, up 2.1%. For FY2026 Bruker guides revenue of $3.52 to $3.56 billion.

### How many employees does Bruker have?

Approximately 11,085 employees at December 31, 2025, about 20.2% of them in the United States.

### Who leads Bruker?

Frank H. Laukien is Chairman, President and CEO, and Gerald N. Herman is Executive Vice President and CFO.

_Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)_
